Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 17/20 | 0.75 |
| ▸ | FAP | Q12884 | 14/20 | 0.75 |
| ▸ | DPP4 | P27487 | 11/20 | 0.75 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377279 | 0.91 | PREP (0.62) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL2310262 | 0.87 | FAP (0.65) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL2306546 | 0.86 | FAP (0.78) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL8250328 | 0.86 | PREP (1.00) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL13377321 | 0.84 | PREP (0.54) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL13377312 | 0.84 | PREP (0.54) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL2837702 | 0.81 | PREP (0.76) | PREPFAPDPP4 | |
| SCHEMBL2837997 | 0.81 | PREP (0.76) | PREPFAPDPP4 | |
| SCHEMBL2315576 | 0.81 | PREP (0.76) | PREPFAPDPP4 | |
| SCHEMBL2307992 | 0.81 | FAP (0.70) | PREPFAPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349995-A1 | SELECTIVE SEPRASE INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| WO-2010036814-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036814-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | PREP 3/4885FAP 4/4885DPP4 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.